Rapid Screening technology for high-affinity, functional and developable fully human antibody
Advanced antibody discovery technologies can serve to address complex cancer targets, and better antibody products and iterations upon the standard can significantly benefit existing therapies that are limited in efficacy and specificity – thus creating a demand for innovative platforms that can generate high-affinity, functional antibodies.
OmniMab library enables discovery of antibodies with broad epitope coverage in two months
The OmniMab antibody library, developed by AP Biosciences, is an advanced platform designed for efficient antibody discovery. Using peripheral blood mononuclear cells (PBMCs) from healthy donors, B cells are isolated and their heavy and light chain antibody fragments are cloned and integrated into a phage display vector. This creates the OmniMab library, which allows the selection of high-affinity antibodies through multiple binding cycles. Targets can be either recombinant proteins or target-expressing cells. After selection, the antibody fragments are sequenced, cloned, and expressed in mammalian cells. Functional candidates are then identified through cell-based assays, ensuring the discovery of potent antibodies for therapeutic development.
Features
- Complete ownership of intellectual property
- Rapid and robust screening for any antigens
- Provide antibody leads with high-affinity antibodies and diverse functionality
